Smart scales could help keep blood cancer patients safe at home

NCT ID NCT06133426

Recruiting now Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at whether a connected scale can help monitor blood cancer patients (with lymphoma or myeloma) during chemotherapy. Thirty patients will weigh themselves daily for about 7 weeks, and their data will be sent to their medical team. The goal is to see if this approach is feasible and if it helps catch problems early.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: connected scale device
What this could lead to: If successful, this could show that remote monitoring with a connected scale helps detect health changes early in blood cancer patients, potentially improving care.
What could go wrong: This is a small, early feasibility study with only 30 participants and no comparison group, so results may not apply broadly. The device may not be easy for all patients to use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGGRESSIVE NON-HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aggressive B-cell non-Hodgkin lymphoma lymphoma, non-Hodgkin, familial non-Hodgkin lymphoma plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYMPHOMA, NON-HODGKIN MYELOMA MULTIPLE

Contacts and locations

Locations

Cochin Hospital
RECRUITING

Paris, 75014, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.